New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
04:55 EDTSI, SI, SI, THOR, THOR, THOR, STJ, STJ, STJ, ATRC, ATRC, ATRC, CADX, CADX, CADX, COV, COV, COV, CRY, CRY, CRY, EW, EW, EW, HTWR, HTWR, HTWR, ISRG, ISRG, ISRG, MDT, MDT, MDT, MYGN, MYGN, MYGN, RTIX, RTIX, RTIX, WTKWY, WTKWY, WTKWYAmerican Association for Thoracic Surgery to hold annual meeting
94th Annual Meeting of AATS is being held in Toronto on April 26-30.
News For SI;RTIX;MYGN;MDT;ISRG;HTWR;EW;CRY;COV;CADX;ATRC;STJ;THOR;WTKWY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 21, 2015
12:33 EDTISRGEarnings Watch: Intuitive Surgical down about 9% since last earnings
Subscribe for More Information
12:33 EDTSTJ, HTWR, THORThoratec jumps after Bloomberg report of St. Jude buyout talks
Subscribe for More Information
12:29 EDTSTJ, THORSt. Jude Medical in talks to acquire Thoratec, Bloomberg reports
Subscribe for More Information
12:21 EDTSTJ, THOROn The Fly: Top stock stories at midday
Subscribe for More Information
12:16 EDTISRGIntuitive Surgical technical comments before results
The stock has been trading in a sideways range from $480 at the low and $512 at the high since April of this year. Those two bounds may help us understand where price may go following earnings. If the news is bearish, a breakdown below $480 would resolve the range bearishly. Next supports to watch as potential downside objectives would be at $475, $470.79, and $467.45. If the news is a bullish surprise, the upper bound of the range at $512 would likely be tested. A breakout above $512 would resolve the range bullishly. Next resistance levels to watch as potential upside objectives would be at $525.57, $538.83, and $542.41.
10:20 EDTTHOR, STJ, HTWRCatalyst behind Thoratec spike higher unclear
The catalyst behind the spike higher in shares of Thoratec (THOR) is unclear to traders and investors. The medical device maker focused on advanced heart failure patients rose as high $62.05 in early trading and its shares remain up 11%, or $5.48, to $54.29. Some vague takeover chatter surfaced, with St. Jude Medical (STJ) as the speculated buyer, but buyout rumors are often the "go-to" reason when stocks spike. Often the moves on rumors are less substantial than Thoratec's spike today. The company's close competitor HeartWare (HTWR) is not seeing any unusual trading thus far today, falling 36c to $78.81 in early trading.
10:14 EDTTHORHigh option volume stocks:
Subscribe for More Information
10:12 EDTTHORThoratec calls active on sharp rally
Thoratec August 55 and 65 calls are active on 260 contracts (50 puts). August call option implied volatility is at 55, September is at 50; compared to its 52-week range of 24 to 51. Active calls suggests traders taking positions for price movement.
09:58 EDTHTWR, THORThoratec jumps 14% to $55.82 in early trading
Subscribe for More Information
08:30 EDTISRGIntuitive Surgical July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
July 20, 2015
08:32 EDTSTJSt. Jude Medical receives FDA approval for MR-conditional 5-column paddle lead
Subscribe for More Information
07:33 EDTWTKWYInternational AIDS Society to hold a conference
Subscribe for More Information
07:10 EDTHTWRHeartWare begins its MVAD System CE Mark international clinical trial
Subscribe for More Information
July 17, 2015
08:07 EDTMDTMedtronic shares undervalued, says Wells Fargo
Subscribe for More Information
06:59 EDTISRGIntuitive Surgical Q2 expectations look reasonable, says Leerink
Subscribe for More Information
July 16, 2015
10:00 EDTMDTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Arc Logistics (ARCX) upgraded to Buy from Hold at Stifel... Dean Foods (DF) upgraded to Buy from Hold at Deutsche Bank... FreightCar America (RAIL) upgraded to Neutral from Sell at UBS... Frontier Communications (FTR) upgraded to Buy from Hold at Jefferies... Google (GOOG) upgraded to Outperform from Market Perform at BMO Capital... Intel (INTC) upgraded to Buy from Hold at Needham... Medtronic (MDT) upgraded to Buy from Neutral at BTIG... Netflix (NFLX) upgraded to Buy from Neutral at Rosenblatt... New Jersey Resources (NJR) upgraded to Buy from Hold at Argus... ONEOK Partners (OKS) upgraded to Outperform from Perform at Oppenheimer... Patterson-UTI (PTEN) upgraded to Overweight from Equal Weight at Morgan Stanley... SJM Holdings (SJMHY) upgraded to Overweight from Underweight at JPMorgan... Statoil (STO) upgraded to Buy from Neutral at Citi... SunOpta (STKL) upgraded to Outperform from Sector Perform at Scotia Howard Weil... Viacom (VIAB) upgraded to Neutral from Sell at Citi... Walgreens Boots Alliance (WBA) upgraded to Outperform from Neutral at Credit Suisse... Werner (WERN) upgraded on 'compelling' valuation at Wells Fargo... Wisconsin Energy (WEC) upgraded to Outperform from Neutral at Baird... voxeljet (VJET) upgraded to Overweight from Neutral at Piper Jaffray.
08:34 EDTSTJSt. Jude Medical receives FDA approval for spinal cord stimulation trial system
St. Jude Medical (STJ) announced it received FDA approval of the Invisible Trial System. The system, which received CE Mark in June 2015, is fully wireless and leverages Apple (AAPL) technology for both the patient and physician controllers. The system is designed to provide patients a more improved and discreet spinal cord stimulation, or SCS, trial experience. "Patients undergoing SCS trials consistently tell us about challenges they find in navigating the SCS trial system, from programming the device, to discomfort from the programming cables, to management of both issues. These hindrances may impede the integration of the technology into their daily activities, which shifts their focus away from evaluating the effectiveness of SCS therapy,” said pain specialist Dr. Jason E. Pope, president of Summit Pain Alliance in Santa Rosa, California. “By providing a discreet trial system, St. Jude Medical will help patients focus more on their potential pain relief and functional improvements, and less about the burdens common to traditional trial systems.”
07:42 EDTMDTMedtronic upgraded to Buy from Neutral at BTIG
BTIG upgraded Medtronic to Buy with a $89 price target. The firm believes the recent pullback has provided a buying opportunity and views the company as well positioned for growth with revenue upside, strong cash deployment, and more Covidien synergies than some expect.
06:52 EDTISRGIntuitive Surgical July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
05:54 EDTMDTMedtronic recalls Shiley neonatal, pediatric tracheostomy tubes
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use